FULL CATALOGUE

BPC-157 10mg is a synthetic 15-amino-acid peptide supplied as a laboratory reference material for controlled in-vitro research involving cellular signalling, connective-tissue biology and related experimental pathways.

TB-500 10mg is a synthetic peptide fragment corresponding to a functional region of Thymosin Beta-4, supplied as a laboratory reference material for research into actin-related signalling, cellular migration and vascular biology.

CJC-1295 (no DAC) 8mg is a 29-amino-acid synthetic GHRH analogue without the Drug Affinity Complex modification, supplied for controlled research into receptor binding and acute somatotropic signalling.

PT-141 10mg is a synthetic cyclic heptapeptide analogue of α-MSH, supplied as a research reference compound for laboratory studies of melanocortin receptor signalling and neuromodulatory pathways.

NAD+ 400mg is a laboratory reference material containing nicotinamide adenine dinucleotide, an endogenous coenzyme central to cellular redox and metabolic research.

A stabilised synthetic analog of Growth Hormone-Releasing Factor (GRF), supplied at 5mg as a higher-yield laboratory format. Suited to extended research programmes or multi-arm experimental designs requiring consistent, larger-volume supply of this well-characterised GHRH analog.

MOTS-C 10mg is a 16-amino-acid mitochondrial-derived peptide encoded within mitochondrial 12S rRNA, supplied for laboratory research into mitochondrial-nuclear signalling and metabolic biology.

KLOW 80mg is a four-peptide research blend combining GHK-Cu, KPV, BPC-157 and TB-500 for controlled laboratory investigation of multiple cellular signalling pathways.

KPV 10mg is a synthetic tripeptide derived from the C-terminal sequence of α-MSH, supplied as a reference material for research into intracellular signalling and cytokine biology.

A cyclic synthetic heptapeptide analog of alpha-melanocyte stimulating hormone (α-MSH), engineered for enhanced receptor binding affinity relative to the native sequence. A well-referenced compound in melanocortin receptor research, with a broad binding profile across the MC receptor family.

Epithalon 10mg is a synthetic tetrapeptide derived from Epithalamin, supplied as a laboratory reference material for research into telomerase-related activity and cellular senescence pathways.

A synthetic heptapeptide analog derived from the ACTH(4-7) sequence, with additional C-terminal modification for enhanced stability. A well-characterised neuropeptide reference compound with an extensive preclinical research history examining central nervous system signalling interactions.

A synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin. Designed for enhanced stability relative to the native tuftsin sequence, and well-characterised as a reference compound in research examining GABAergic signalling pathway interactions and central nervous system receptor dynamics.

GLOW 70mg is a multi-peptide research blend containing BPC-157, TB-500 and GHK-Cu, supplied for laboratory investigation of extracellular-matrix biology and related cellular signalling pathways.

GHK-Cu 50mg is a copper-binding tripeptide supplied as a laboratory research material for research into cellular signalling, fibroblast biology and related connective-tissue pathways.

DSIP 10mg is a naturally occurring nonapeptide reference compound studied in laboratory research involving central nervous system peptide signalling, neuromodulatory pathways and hypothalamic regulation.

SS-31 8mg is a synthetic mitochondria-targeted tetrapeptide designed to bind cardiolipin on the inner mitochondrial membrane and supplied for research into mitochondrial bioenergetics and oxidative-stress pathways.

Kisspeptin-10 5mg is a synthetic decapeptide fragment of the kisspeptin family, supplied as a research reference compound for KISS1R signalling and hypothalamic-pituitary-gonadal axis studies.

A naturally occurring tripeptide composed of glutamate, cysteine, and glycine, central to endogenous antioxidant defence. Characterised by its unique γ-linked structure conferring resistance to standard peptidase cleavage, and well-characterised as a reference compound in research examining cellular redox balance and oxidative stress pathway dynamics.

A synthetic small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). Designed for high target specificity and oral bioavailability in research settings, and well-characterised as a reference compound in research examining cellular NAD+ metabolism and adipocyte energy pathway dynamics.

A synthetic modified fragment (176-191) of the human growth hormone polypeptide, isolated for its lipolytic activity independent of GH receptor-mediated growth effects. Designed for enhanced stability relative to the native hGH sequence, and well-characterised as a reference compound in research examining lipid metabolism pathway interactions and adipose tissue signalling dynamics.

A naturally occurring copper-binding tripeptide (Glycyl-L-histidyl-L-lysine) supplied at 100mg as a high-volume laboratory reference standard. Intended for extended research programmes or multi-assay panels requiring a consistent batch supply of this well-characterised compound.

A synthetic long-acting analogue of Insulin-like Growth Factor-1, engineered with a 13-amino acid N-terminal extension and an arginine substitution at position 3. One of the most widely referenced growth factor peptides in in-vitro research, with a significantly extended functional half-life compared to native IGF-1 due to markedly reduced binding affinity for IGF binding proteins (IGFBPs).

A synthetic pentapeptide and selective growth hormone secretagogue, designed as a ghrelin receptor (GHSR-1a) agonist. Distinguished from earlier growth hormone releasing peptides by its high selectivity — stimulating GH release without significant concurrent effects on cortisol or prolactin in experimental models. Widely used as a reference compound in GH secretagogue research due to its clean pharmacological profile and well-documented receptor binding characteristics.

A synthetic 36-amino acid acylated triagonist peptide with agonist activity at the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. One of the most pharmacologically sophisticated incretin-class peptides studied to date, featuring a C20 fatty acid modification that extends plasma half-life through albumin binding. Extensively referenced in metabolic research literature examining combined incretin receptor signalling, energy homeostasis, and adipose biology in controlled laboratory settings.

A synthetic 39-amino acid acylated dual agonist peptide with activity at both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Based on a modified GIP peptide backbone with an Aib² substitution for protease resistance and a C18 fatty diacid modification at Lys²⁶ for extended half-life via albumin binding. The first approved dual incretin receptor agonist in its class, and one of the most extensively published synthetic peptides in metabolic and obesity research.